| Oct 25 |
Purple Biotech Presents New Data for its Novel Tri-Specific T Cell and NK Cell Engagers Antibody Platform, CAPTN-3, at the EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics
|
| Oct 11 |
Purple Biotech Unveils CAPTN-3 Cancer Therapy
|
| Oct 10 |
Purple Biotech to Present Data for its Tri-Specific Antibody Platform—CAPTN-3—at the EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics
|
| Sep 18 |
Purple Biotech Reports Additional Positive Interim Data from its Randomized Phase 2 Study with its Lead Oncology Therapeutic Candidate CM24
|
| Sep 16 |
Upcoming Stock Splits This Week (September 16 to September 20) – Stay Invested
|
| Sep 16 |
Why Exicure Shares Are Trading Higher By Over 49%; Here Are 20 Stocks Moving Premarket
|
| Sep 10 |
Purple Biotech to Present Data for its Lead Oncology Drug CM24 at the AACR Special Conference on Advances in Pancreatic Cancer Research
|
| Aug 30 |
Purple Biotech to Participate at H.C. Wainwright 26th Annual Global Investment Conference
|
| Aug 16 |
Purple Biotech GAAP EPADS of -$0.09
|
| Aug 16 |
Purple Biotech Reports Second Quarter 2024 Financial Results and Business Highlights
|
